C Capula1, T Mazza, R Vero, G Costante. 1. Struttura Operativa Complessa Endocrinologia-Diabetologia, Azienda Ospedaliera "Pugliese-Ciaccio", Catanzaro, Italy. carmelo.capula@yahoo.it.
Abstract
BACKGROUND/AIMS: The use of glycated hemoglobin (HbA1c) measurement in gestational diabetes mellitus (GDM) is controversial. Aim of the present study was to determine HbA1c levels in a series of GDM patients, in order to verify the possible contribution of HbA1c to GDM management. MATERIALS/SUBJECTS AND METHODS: The study included 148 caucasian GDM patients. GDM screening was performed between the 24th and the 28th week of gestation by a two-step procedure, according to the 4th and 5th International Workshop Conference on Gestational Diabetes Mellitus recommendations. Exclusion criteria were: preexisting diabetes, corticosteroid therapy, history of asthma or hypertension, known fetal anomaly, history of previous stillbirth, preterm delivery considered to be likely for either maternal disease or fetal conditions. HBA1c was determined by a standard HPLC technique. RESULTS: At GDM diagnosis, all HbA1c levels were ≤ 6% and the greatest frequency (71/148; 48.0%) of HbA1c values resulted in the range 5.0-5.3%. This frequency increased to 54% before delivery. A significant correlation between HbA1c values at GDM diagnosis and individual BMI prior to conception was observed. The proportion of pregnancies presenting negative outcomes increased progressively with increasing HbA1c levels, from 6.2% (1/16) for HbA1c levels <5% to 18.3% (13/71) for HbA1c 5.0-5.3%, to 37.8% (17/45) in patients with HBA1c levels 5.4-5.6%, to 56.2% (9/16) for HbA1c levels >5.6%. ROC analysis showed that HbA1c at diagnosis and before delivery resulted a good predictor of adverse pregnancy outcome. CONCLUSIONS: The present results indicate that HbA1c levels could be of help in predicting adverse pregnancy events.
BACKGROUND/AIMS: The use of glycated hemoglobin (HbA1c) measurement in gestational diabetes mellitus (GDM) is controversial. Aim of the present study was to determine HbA1c levels in a series of GDM patients, in order to verify the possible contribution of HbA1c to GDM management. MATERIALS/SUBJECTS AND METHODS: The study included 148 caucasian GDM patients. GDM screening was performed between the 24th and the 28th week of gestation by a two-step procedure, according to the 4th and 5th International Workshop Conference on Gestational Diabetes Mellitus recommendations. Exclusion criteria were: preexisting diabetes, corticosteroid therapy, history of asthma or hypertension, known fetal anomaly, history of previous stillbirth, preterm delivery considered to be likely for either maternal disease or fetal conditions. HBA1c was determined by a standard HPLC technique. RESULTS: At GDM diagnosis, all HbA1c levels were ≤ 6% and the greatest frequency (71/148; 48.0%) of HbA1c values resulted in the range 5.0-5.3%. This frequency increased to 54% before delivery. A significant correlation between HbA1c values at GDM diagnosis and individual BMI prior to conception was observed. The proportion of pregnancies presenting negative outcomes increased progressively with increasing HbA1c levels, from 6.2% (1/16) for HbA1c levels <5% to 18.3% (13/71) for HbA1c 5.0-5.3%, to 37.8% (17/45) in patients with HBA1c levels 5.4-5.6%, to 56.2% (9/16) for HbA1c levels >5.6%. ROC analysis showed that HbA1c at diagnosis and before delivery resulted a good predictor of adverse pregnancy outcome. CONCLUSIONS: The present results indicate that HbA1c levels could be of help in predicting adverse pregnancy events.
Authors: Lene R Nielsen; Pia Ekbom; Peter Damm; Charlotte Glümer; Merete M Frandsen; Dorte M Jensen; Elisabeth R Mathiesen Journal: Diabetes Care Date: 2004-05 Impact factor: 19.112
Authors: Caroline A Crowther; Janet E Hiller; John R Moss; Andrew J McPhee; William S Jeffries; Jeffrey S Robinson Journal: N Engl J Med Date: 2005-06-12 Impact factor: 91.245
Authors: M Cornblath; J M Hawdon; A F Williams; A Aynsley-Green; M P Ward-Platt; R Schwartz; S C Kalhan Journal: Pediatrics Date: 2000-05 Impact factor: 7.124
Authors: W Ricart; J López; J Mozas; A Pericot; M A Sancho; N González; M Balsells; R Luna; A Cortázar; P Navarro; O Ramírez; B Flández; L F Pallardo; A Hernández-Mijas; J Ampudia; J M Fernández-Real; R Corcoy Journal: Diabetologia Date: 2005-07-29 Impact factor: 10.122
Authors: Andrea Mosca; Renata Paleari; Maria G Dalfrà; Graziano Di Cianni; Ilaria Cuccuru; Giovanni Pellegrini; Lucia Malloggi; Matteo Bonomo; Simona Granata; Ferruccio Ceriotti; Maria T Castiglioni; Marco Songini; Giuliana Tocco; Michela Masin; Mario Plebani; Annunziata Lapolla Journal: Clin Chem Date: 2006-04-06 Impact factor: 8.327
Authors: Mark B Landon; Catherine Y Spong; Elizabeth Thom; Marshall W Carpenter; Susan M Ramin; Brian Casey; Ronald J Wapner; Michael W Varner; Dwight J Rouse; John M Thorp; Anthony Sciscione; Patrick Catalano; Margaret Harper; George Saade; Kristine Y Lain; Yoram Sorokin; Alan M Peaceman; Jorge E Tolosa; Garland B Anderson Journal: N Engl J Med Date: 2009-10-01 Impact factor: 91.245
Authors: Lynn P Lowe; Boyd E Metzger; Alan R Dyer; Julia Lowe; David R McCance; Terence R J Lappin; Elisabeth R Trimble; Donald R Coustan; David R Hadden; Moshe Hod; Jeremy J N Oats; Bengt Persson Journal: Diabetes Care Date: 2012-02-01 Impact factor: 19.112
Authors: R Saucedo; G Rico; G Vega; L Basurto; L Cordova; R Galvan; M Hernandez; E Puello; A Zarate Journal: J Endocrinol Invest Date: 2014-12-06 Impact factor: 4.256